Sharps Technology Partners with The Tie to Strengthen Solana's Institutional Infrastructure
Sharps Technology and The Tie announced a strategic collaboration to strengthen Solana's institutional infrastructure and expand institutional access to the ecosystem. Under the collaboration, STSS will delegate a portion of its SOL treasury holdings, currently more than 2 million SOL, to Stakin by The Tie, which operates non-custodial validator infrastructure across 40+ proof-of-stake networks. "This collaboration with The Tie reflects STSS's commitment to expanding institutional participation in the Solana ecosystem through credible infrastructure and trusted institutional networks," said Alice Zhang, Chief Investment Officer of STSS. "The Tie has built one of the most respected platforms in institutional crypto. By delegating to Stakin by The Tie and engaging directly with their institutional community, we can elevate Solana's visibility among the institutions that matter most, while maintaining full custody and control of our assets."
Trade with 70% Backtested Accuracy
Analyst Views on STSS
About STSS
About the author


Strategic Collaboration: SHARPS Technology and The Tie have announced a strategic collaboration aimed at enhancing institutional participation in the Solana ecosystem.
Focus on Advancement: The partnership is designed to advance the integration of technology and institutional engagement within the Solana blockchain network.

Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.

Collaboration with Coinbase: Sharps Technology is expanding its Solana digital asset treasury strategy through a strategic partnership with Coinbase Global, utilizing Coinbase Prime's custody and OTC desk services.
Acquisition of SOL: The company has acquired over 2 million SOL, valued at over $400 million, with the cryptocurrency currently trading above $210.
Strategic Collaboration: Sharps Technology, Inc. has partnered with Coinbase to enhance its Solana digital asset treasury strategy, having acquired over 2 million SOL valued at over $400 million.
Utilization of Coinbase Services: The collaboration will leverage Coinbase's custody infrastructure and OTC desk products, aiming to support the global adoption of digital assets while ensuring secure and regulated service.

Stock Repurchase Program: Sharps Technology, Inc. has authorized a stock repurchase program to buy back up to $100 million of its outstanding common stock, aiming to enhance shareholder value and manage its capital structure.
Market Reaction: Following the announcement, Sharps Technology's stock rose by 8.41% in pre-market trading, reaching $7.35 on the Nasdaq.
Stock Repurchase Program: Sharps Technology (NASDAQ: STSS) has launched a stock repurchase program to buy back up to $100 million of its common stock, which is approximately 55.5% of its market cap of $180.35 million as of October 1, 2025.
Market Reaction: Following the announcement, shares of STSS increased by 1.92% in premarket trading on Thursday.







